TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04820335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured External Memory Aid Treatment (SEMAT)
Description: During the 7 weeks of treatment, the interventionist will teach 3 categories of external memory aids (calendars, timers, notes) following an already-developed detailed treatment manual (described here briefly).~Week 1: Introduction of External Memory Aid Treatment and Person-Centered Goal Setting. Weeks 2-7. In the next six weeks, three categories of external memory aids will be taught: calendars, timers, and notes. The focus of the first session will be how to use the strategies, and the second session will build awareness of when to use these strategies during everyday tasks. Within each category, three types of strategies will be taught to participants. Within each session, learning phases will follow training stages from compensatory learning theory: 1) acquisition phase, 2) application phase, and 3) an adaptation phase.
Study: NCT06234605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-7366
Description: HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-7366
Description: HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan is a potent and selective HIF-2α inhibitor
Study: NCT06410118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DreamChanger+IRT
Description: Families will receive the DreamChanger remote along with 3 instructional videos for parents, explaining how to present the remote to children, and how to rehearse alternative dream imagery using the DreamChanger remote.
Study: NCT06580782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate 500 MG
Description: Calcium Carbonate 500mg, orally, every 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Dose Synthetic Pitocin
Description: The participant will receive thestandard-dose synthetic oxytocin for labor induction or augmentation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Synthetic Pitocin
Description: The participant will receive thestandard-dose synthetic oxytocin for labor induction or augmentation.
Study: NCT06516510

Intervention type: DRUG
Group type: OTHER
Intervention: lutetium (177Lu) rhPSMA 10.1 and Pluvicto®
Description: Radiopharmaceutical
Study: NCT04982575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide 2.4 mg
Description: Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide 2.4 mg
Description: Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (cagrilintide)
Description: Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Study: NCT05222178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMI-103
Description: HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene
Study: NCT06025487

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bexsero
Description: two doses of Bexsero are applied intramuscularly with a one-month interval between doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bexsero
Description: two doses of Bexsero are applied intramuscularly with a one-month interval between doses
Study: NCT04741945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 2000 mg/day metformin for 12 months (1000 mg b.i.d.) with a slow up-titration six weeks prior to full dose treatment.
Study: NCT05722340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-intubated video-assisted thoracic surgery (NIVATS) for lung biopsy
Description: An epidural anaesthesia associated with mild sedation requiring no ventilation is used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubated general anaesthesia video-assisted thoracic surgery (IGAVATS) for lung biopsy
Description: Uses a traditional deep anaesthesia and one-lung ventilation
Study: NCT06350331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile venous thromboembolism application (mVTEA)
Description: mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, photo, and voice interactions.
Study: NCT06567366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Description: Participants will receive CAR T-cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR T-cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15.~Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-6 (as relevant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
Study: NCT06245369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: learning modules (within app)
Description: Behavioral:~Participants will have access to a weekly learning module created as Kahoot courses. Each module will include some or all (as applicable) of the following:~* A brief educational video discussing the week's topic~* A brief video sharing ideas for applying the educational content into daily life~* PDF of meal swap examples~* A weekly goal or challenge~* Recipes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: learning modules (within app)
Description: Behavioral:~Participants will have access to a weekly learning module created as Kahoot courses. Each module will include some or all (as applicable) of the following:~* A brief educational video discussing the week's topic~* A brief video sharing ideas for applying the educational content into daily life~* PDF of meal swap examples~* A weekly goal or challenge~* Recipes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SWITCH app (self-regulation features) - Experimental
Description: Behavioral:~Diet (track by in app database). App homepage displays dietary intake graph -circles -. Participants will see an empty circles for the goal nutrients at the start of each day, which will fill up as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely full.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SWITCH app (self-regulation features) - Comparator
Description: Diet (track by in app database). App homepage displays dietary intake graph -circles -.~Participants allocated to the control group, tracking intake of nutrients to lower, will see a full circle at the start of each day which depletes, or empties, as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely empty and the reported totals below the intake circles will display the current intake totals.
Study: NCT06567080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWCAR201
Description: JWCAR201 is a autologous CAR-T targeting CD19/CD20
Study: NCT06146504

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CanXida Remove (Formula RMV)
Description: Supplement composed of a 12 ingredient anti-fungal, anti-bacterial \& anti-parasite formula.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product containing Dicalcium Phosphate, Magnesium Stearate, Stearic Acid, Croscarmellose Sodium, and Silica.
Study: NCT06126523

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Extracorporeal Shock Wave Therapy ONCE
Description: rESWT application ONCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Extracorporeal Shock Wave Therapy ONCE
Description: rESWT application ONCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Extracorporeal Shock Wave Therapy TWİCE
Description: rESWT application TWİCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~A total of 2 sessions of rESWT will be applied on the same day after BTX-A injection and on the 7th day after BTX-A.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Radial Extracorporeal Shock Wave Therapy SHAM
Description: Radial Extracorporeal Shock Wave Therapy- SHAM The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Sham ESWT will be administered with the r-ESWT probe. The device will be switched on, the frequency, pressure and duration values will be set and then the device will be switched off and the probe will be kept in equal time with the active treatment, by playing a sound previously recorded during the real application.
Study: NCT05835999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 0.5 MG once per day
Description: Everolimus is considered an mTOR kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 5 MG once per week
Description: Everolimus is considered an mTOR kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo once per day
Description: No therapeutic effect

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo once per day
Description: No therapeutic effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo once per week
Description: No therapeutic effect

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo once per week
Description: No therapeutic effect
Study: NCT06565598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-layer robot-assisted transperitoneal retroperitoneal tubeless radical nephrectomy
Description: Free through the single layer of the posterior abdominal cavity
Study: NCT06096181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil TIVA
Description: Remifentanil is more commonly used in the TIVA combination for pediatric patients having this surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine TIVA
Description: Dexmedetomidine is less commonly used in the TIVA combination for pediatric patients having this surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol TIVA
Description: Propofol is an anesthetic drug that causes sleep during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol TIVA
Description: Propofol is an anesthetic drug that causes sleep during surgery.
Study: NCT06536725

Intervention type: OTHER
Intervention: Building Organoid-on-chips models
Description: This project obtains surgical or biopsy samples from prostate cancer patients with visceral metastasis for the construction of organoids.
Study: NCT06542796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunotherapy combined with targeted therapy
Description: Immunotherapy combined with targeted therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment plan
Description: Standard treatment plan
Study: NCT06072131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belinostat Injection
Description: Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belinostat Injection
Description: Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pralatrexate Injection
Description: Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pralatrexate Injection
Description: Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: CHOP is the comparator arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: CHOP is the comparator arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: CHOP is the comparator arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COP
Description: COP is given in combination with Pralatrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COP
Description: COP is given in combination with Pralatrexate
Study: NCT06043219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Action observation is defined as watching human movement either via a pre-recorded video or a live demonstration (Eaves et al, 2022). In the current study action observation will be via a pre-recorded video.~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Action observation is defined as watching human movement either via a pre-recorded video or a live demonstration (Eaves et al, 2022). In the current study action observation will be via a pre-recorded video.~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Motor imagery practice is defined as the structured engagement in motor imagery over time for the purpose of acquiring and enhancing motor skills (Eaves et al, 2022).~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Teaching
Description: Traditional anatomical teaching via a powerpoint slide deck

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Teaching
Description: Traditional anatomical teaching via a powerpoint slide deck

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Teaching
Description: Traditional anatomical teaching via a powerpoint slide deck
Study: NCT04534387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spanish-Language Hearing Loss Toolkit for Self-Management
Description: The materials include printed information and images designed to increase hearing loss knowledge and focus on self-management topics such as the fundamentals of the ear and hearing, communication strategies, speech understanding in noise, and hearing technology.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Speech-Language-Hearing Association (ASHA) Audiology Series Spanish Language Handouts
Description: Standard of care patient education handouts developed by ASHA in the Spanish language.
Study: NCT04631406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neural Stem Cells
Description: NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke
Study: NCT04879992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study: NCT05339256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine SL
Description: Up to 24 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine SL
Description: Up to 24 mg per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Telehealth MOUD, utilizing a standardized protocol for each healthcare provider session
Study: NCT04879992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline,Metronidazole
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin rifabutin
Description: Antibiotics for H. pylori eradication
Study: NCT05339256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person treatment as usual
Description: in-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.
Study: NCT06540898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Eating and Movement Program
Description: This intervention integrates mindful eating practices and mindful movement into physical education classes for a duration of 8 weeks.~Each session begins with a 10-minute mindful eating practice designed to enhance participants; awareness of hunger and fullness cues, the sensory experience of eating, and their emotional responses to food. The program is to address food literacy, physical literacy, and social-emotional learning. It applied the principles of various established mindfulness and cognitive behavioral therapies and the book The Joy of Half a Cookie: Using Mindfulness to Lose Weight and End the Struggle with Food . It is grounded in the components of Mindfulness-Based Eating Awareness Training. The movement practices include basic poses in pairs and groups, and breath awareness techniques to facilitate a mindful connection with physical sensations and mental states.
Study: NCT05652036

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradetrusor Botox Injections
Description: 100 units of OnabotuliumtoxinA is injected into the detrusor muscle in 1 mL aliquots using a cystoscope.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradetrusor Botox Injections
Description: 100 units of OnabotuliumtoxinA is injected into the detrusor muscle in 1 mL aliquots using a cystoscope.
Study: NCT05830123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study: NCT04886232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VP1 Lido US
Description: Hyaluronic acid dermal filler containing lidocaine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VP1 Lido US
Description: Hyaluronic acid dermal filler containing lidocaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Lyft Lidocaine
Description: Hyaluronic acid dermal filler containing lidocaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Lyft Lidocaine
Description: Hyaluronic acid dermal filler containing lidocaine
Study: NCT04960774

Intervention type: OTHER
Intervention: Observational study, no intervention
Description: Observational study, no intervention

Intervention type: OTHER
Intervention: Observational study, no intervention
Description: Observational study, no intervention
Study: NCT06567522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumbar Erector Spinae Plane Block. L bupivacaína 0.25%
Description: Ultrasound-guided ESP-L shall be carried out at the L3-14 level with 30 mL of levobupivacaine 0.25%